Genentech:Phase III Data Shows Single-Dose Xofluza Effectively Reduces Influenza Transmission By 32%
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Genentech, a member of the Roche Group (RHHBY), announced that the New England Journal of Medicine has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza (baloxavir marboxil). The trial met its primary endpoint, showing that a single, oral do
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2074435669-2cf1ba50572d485f920189bdd57bb651.jpg "Strategies for Trading Fibonacci Retracement Levels")
:max_bytes(150000):strip_icc():format(jpeg)/who-or-what-is-dow-jones-final-f6494139af214d2b92c4e73f380092a5.png "Who or What Is Dow Jones?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1352017390-ec671bb197624f1cade807ebb61a7635.jpg "How To Set Up a Backdoor Roth IRA: A Step-by-Step Guide")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-best-plumbers-liability-insurance-of-2023-7500943-7642156690614509b3dff28f75a440d1.jpg "How and Where Is Revenue From Barter Transactions Recognized?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1167627082-0192a4b1af0f42438a055031c86bfd4c.jpg "<div>Private Jet Charter vs. First-Class: What's the Difference?</div>")